$ADAP
Adaptimmune Therapeutics PLC Stock $adap

$adap Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000155837021001827 Filed on February 25, 2021

Income Statement

Concept	2019 Q4	2018	2017 Q4
Revenue	$730.0K	$59.51M	$4.270M
YoY Change	-50.68%	57.3%	-50.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.73M	$43.60M	$8.820M
YoY Change	-0.83%	40.15%	38.9%
% of Gross Profit
Research & Development	$20.35M	$98.27M	$25.15M
YoY Change	-10.63%	12.45%	49.26%
% of Gross Profit
Depreciation & Amortization	$2.090M	$7.188M	$1.730M
YoY Change	-0.48%	32.62%	96.59%
% of Gross Profit
Operating Expenses	$31.08M	$98.27M	$33.97M
YoY Change	-7.47%	-17.07%	46.49%
Operating Profit		-$82.37M
YoY Change
Interest Expense	$450.0K	$380.0K	$770.0K
YoY Change	-56.73%	-82.96%	185.19%
% of Operating Profit
Other Income/Expense, Net	$630.0K	-$15.50M	$1.500M
YoY Change	-112.65%	-277.36%	-354.24%
Pretax Income	-$29.28M	-$95.02M	-$27.43M
YoY Change	-18.76%	36.34%	83.11%
Income Tax	$90.00K	$497.0K	-$170.0K
% Of Pretax Income
Net Earnings	-$29.36M	-$95.51M	-$27.26M
YoY Change	-18.83%	36.18%	76.9%
Net Earnings / Revenue	-4021.92%	-160.51%	-638.41%
Basic Earnings Per Share
Diluted Earnings Per Share	-$46.53K	-$163.4K	-$48.55K
COMMON SHARES
Basic Shares Outstanding	631.0M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$89.54M	$205.1M	$208.3M
YoY Change	-56.35%	-1.54%	14.77%
Cash & Equivalents	$50.41M	$68.40M	$88.30M
Short-Term Investments	$39.13M	$136.8M	$124.2M
Other Short-Term Assets	$1.809M	$7.800M	$21.70M
YoY Change	312.07%	-64.06%	37.34%
Inventory
Prepaid Expenses	$8.395M
Receivables	$0.00	$200.0K	$200.0K
Other Receivables	$20.70M	$18.00M	$0.00
Total Short-Term Assets	$120.5M	$231.1M	$230.2M
YoY Change	-47.86%	0.39%	15.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$31.07M	$36.10M	$40.70M
YoY Change	-13.98%	-11.3%	45.88%
Goodwill
YoY Change
Intangibles	$2.198M
YoY Change	49.22%
Long-Term Investments
YoY Change
Other Assets	$7.000M	$8.100M	$8.900M
YoY Change	-13.58%	-8.99%	34.85%
Total Long-Term Assets	$61.05M	$45.60M	$50.90M
YoY Change	33.77%	-10.41%	42.58%
TOTAL ASSETS
Total Short-Term Assets	$120.5M	$231.1M	$230.2M
Total Long-Term Assets	$61.05M	$45.60M	$50.90M
Total Assets	$181.5M	$276.7M	$281.1M
YoY Change	-34.4%	-1.57%	19.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.357M	$4.100M	$8.400M
YoY Change	55.69%	-51.19%	-26.32%
Accrued Expenses	$23.36M	$20.00M	$26.80M
YoY Change	14.78%	-25.37%	63.41%
Deferred Revenue	$2.128M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.34M	$24.40M	$74.30M
YoY Change	40.53%	-67.16%	84.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$598.0K	$5.400M	$3.800M
YoY Change	-88.95%	42.11%	-86.48%
Total Long-Term Liabilities	$598.0K	$5.400M	$3.800M
YoY Change	-88.95%	42.11%	-86.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.34M	$24.40M	$74.30M
Total Long-Term Liabilities	$598.0K	$5.400M	$3.800M
Total Liabilities	$57.91M	$29.90M	$78.20M
YoY Change	93.98%	-61.76%	14.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$455.7M
YoY Change	43.07%
Common Stock	$943.0K
YoY Change	0.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$123.6M	$246.9M	$203.0M
YoY Change
Total Liabilities & Shareholders Equity	$181.5M	$276.7M	$281.1M
YoY Change	-34.4%	-1.57%	19.87%

Cashflow Statement

Concept	2019 Q4	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$29.36M	-$95.51M	-$27.26M
YoY Change	-18.83%	36.18%	76.9%
Depreciation, Depletion And Amortization	$2.090M	$7.188M	$1.730M
YoY Change	-0.48%	32.62%	96.59%
Cash From Operating Activities	-$12.53M	-$104.4M	-$21.36M
YoY Change	-60.46%	92.17%	-1001.27%
INVESTING ACTIVITIES
Capital Expenditures	-$610.0K	$3.910M	-$1.930M
YoY Change	177.27%	-115.63%	-72.15%
Acquisitions
YoY Change
Other Investing Activities	$24.30M	-$12.75M	-$38.08M
YoY Change	-146.56%	-87.38%	-259.46%
Cash From Investing Activities	$23.69M	-$17.46M	-$40.01M
YoY Change	-145.2%	-86.15%	-335.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$99.65M
YoY Change		-3.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	102.7M	0.000
YoY Change	-100.0%	-0.85%	-100.0%
NET CHANGE
Cash From Operating Activities	-12.53M	-104.4M	-21.36M
Cash From Investing Activities	23.69M	-17.46M	-40.01M
Cash From Financing Activities	0.000	102.7M	0.000
Net Change In Cash	11.16M	-15.82M	-61.37M
YoY Change	-113.29%	-79.41%	-417.16%
FREE CASH FLOW
Cash From Operating Activities	-$12.53M	-$104.4M	-$21.36M
Capital Expenditures	-$610.0K	$3.910M	-$1.930M
Free Cash Flow	-$11.92M	-$108.3M	-$19.43M
YoY Change	-62.12%	269.49%	-308.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	928754958
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable
CY2020Q4	adap	Clinical Materials Noncurrent ClinicalMaterialsNoncurrent
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001621227
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	631003568
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-37368
CY2020	dei	Entity Registrant Name EntityRegistrantName	ADAPTIMMUNE THERAPEUTICS PLC
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Jubilee Avenue, Milton Park
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Abingdon, Oxfordshire
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	OX14 4RX
CY2020	dei	Entity Address Country EntityAddressCountry	GB
CY2020	dei	City Area Code CityAreaCode	44
CY2020	dei	Local Phone Number LocalPhoneNumber	1235 430000
CY2020	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing
CY2020	dei	Trading Symbol TradingSymbol	ADAP
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1359787192
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	930827670
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56882000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50412000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	311335000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	39130000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	139000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29796000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	30947000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	398152000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	120489000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4602000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4496000
CY2019Q4	adap	Clinical Materials Noncurrent ClinicalMaterialsNoncurrent	2503000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18880000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20789000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27778000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31068000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1730000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2198000
CY2020Q4	us-gaap	Assets Assets	451142000
CY2019Q4	us-gaap	Assets Assets	181543000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6389000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6357000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2773000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2493000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27079000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23363000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2832000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2128000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39073000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34341000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20938000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22966000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	49260000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	644000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	598000
CY2020Q4	us-gaap	Liabilities Liabilities	109915000
CY2019Q4	us-gaap	Liabilities Liabilities	57905000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1038249630
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	928754958
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	785857300
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631003568
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1325000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	943000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	935706000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	585623000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10048000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7264000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585756000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-455664000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341227000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	123638000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	451142000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	181543000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3958000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59505000
CY2020	adap	Operating Losses Accrued On Firm Purchase Commitments OperatingLossesAccruedOnFirmPurchaseCommitments	0
CY2019	adap	Operating Losses Accrued On Firm Purchase Commitments OperatingLossesAccruedOnFirmPurchaseCommitments	5000000
CY2018	adap	Operating Losses Accrued On Firm Purchase Commitments OperatingLossesAccruedOnFirmPurchaseCommitments	0
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	91568000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97501000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	98269000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45795000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43391000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43601000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	137363000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	140892000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	141870000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-133405000
CY2018	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	2849000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1162000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	75000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15501000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-129930000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-136923000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-95017000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-139770000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-82365000
CY2020	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	2313000
CY2019	us-gaap	Interest Income Debt Securities Available For Sale Operating InterestIncomeDebtSecuritiesAvailableForSaleOperating	2772000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	162000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	242000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	497000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-130092000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-137165000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95514000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	854783763
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	629805218
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	584338942
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-130092000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-137165000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95514000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-19220000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9478000
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	8260000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	16364000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	11783000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	161000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	207000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1145000
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	89000
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	13000
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-2473000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-132876000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-134666000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83636000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	202984000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99653000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3037000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	11878000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16202000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95514000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	246885000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	366000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2499000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11053000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-137165000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	123638000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5663000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2784000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10414000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-130092000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341227000
CY2020	us-gaap	Profit Loss ProfitLoss	-130092000
CY2019	us-gaap	Profit Loss ProfitLoss	-137165000
CY2018	us-gaap	Profit Loss ProfitLoss	-95514000
CY2020	us-gaap	Depreciation Depreciation	6627000
CY2019	us-gaap	Depreciation Depreciation	7172000
CY2018	us-gaap	Depreciation Depreciation	7188000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	967000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	838000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	622000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	10414000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	11053000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	16202000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1333000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1076000
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-9747000
CY2020	adap	Amortization Accretion Of Marketable Securities AmortizationAccretionOfMarketableSecurities	3836000
CY2019	adap	Amortization Accretion Of Marketable Securities AmortizationAccretionOfMarketableSecurities	-185000
CY2018	adap	Amortization Accretion Of Marketable Securities AmortizationAccretionOfMarketableSecurities	237000
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-55000
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-13000
CY2018	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2473000
CY2020	adap	Increase Decrease In Current Assets IncreaseDecreaseInCurrentAssets	-1747000
CY2019	adap	Increase Decrease In Current Assets IncreaseDecreaseInCurrentAssets	1436000
CY2018	adap	Increase Decrease In Current Assets IncreaseDecreaseInCurrentAssets	5162000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2458000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1450000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-742000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	3867000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	5508000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-2702000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	366000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3037000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	340051000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	366000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	102690000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-960000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	27284000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	150787000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-278924000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	94945000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17457000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	99653000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5663000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	47973000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2095000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-38221000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53591000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-112507000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-104388000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2341000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1592000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3910000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	565000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1482000
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	798000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	105022000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	125303000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	138038000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	381040000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-372000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3335000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6576000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17568000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15820000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54908000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72476000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88296000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61484000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54908000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72476000
CY2020	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	6216000
CY2019	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	3426000
CY2018	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	3114000
CY2020	adap	Amortization Accretion Of Marketable Securities AmortizationAccretionOfMarketableSecurities	3836000
CY2019	adap	Amortization Accretion Of Marketable Securities AmortizationAccretionOfMarketableSecurities	-185000
CY2018	adap	Amortization Accretion Of Marketable Securities AmortizationAccretionOfMarketableSecurities	237000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	75000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	201000
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	258000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585756000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to </span>people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies<span style="white-space:pre-wrap;">, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of </span>$585,756,000 as of December 31, 2020.</p>
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b> <b style="font-weight:bold;">Use of estimates in financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to revenue recognition, estimation of the incremental borrowing rate for operating leases, and valuation allowances relating to deferred tax assets. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56882000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50412000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4602000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4496000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61484000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54908000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	105022000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	125303000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	138038000
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	89000
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	13000
CY2018	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	-2473000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	3399000
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1904000
CY2020	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	889000
CY2019	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	4556000
CY2018	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	210000
CY2020	adap	Reimbursement Of Research And Development Tax And Expenditure Credit ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit	19442000
CY2019	adap	Reimbursement Of Research And Development Tax And Expenditure Credit ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit	18649000
CY2018	adap	Reimbursement Of Research And Development Tax And Expenditure Credit ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit	17299000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1847000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2070000
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3836000
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-185000
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	237000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-130092000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-137165000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95514000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-130092000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-137165000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-95514000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	854783763
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	629805218
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	584338942
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020	adap	Number Of Contracts With Customer NumberOfContractsWithCustomer	2
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3958000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59505000
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	49964000
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2128000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	52092000
CY2020	adap	Number Of Independent Targets NumberOfIndependentTargets	2
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56882000
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	311335000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	4602000
CY2020	adap	Concentration Risk Customers Number ConcentrationRiskCustomersNumber	2
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	139000
CY2020Q4	adap	Receivables Past Due Amount ReceivablesPastDueAmount	0
CY2020Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	1.36
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	20585000
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	19284000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6314000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8395000
CY2020Q4	adap	Clinical Materials Current ClinicalMaterialsCurrent	2086000
CY2019Q4	adap	Clinical Materials Current ClinicalMaterialsCurrent	1459000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	811000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1809000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29796000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	30947000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	58875000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	54717000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31097000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23649000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27778000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31068000
CY2020	us-gaap	Depreciation Depreciation	6627000
CY2019	us-gaap	Depreciation Depreciation	7172000
CY2018	us-gaap	Depreciation Depreciation	7188000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4862000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4299000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3132000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2101000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1730000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2198000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	967000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	838000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	622000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	933000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	671000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	135000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	4044000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	4017000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	359000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	319000
CY2020	us-gaap	Lease Cost LeaseCost	4403000
CY2019	us-gaap	Lease Cost LeaseCost	4336000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	3769000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	4063000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072
CY2020Q4	adap	Accrued Liabilities For Purchases Current AccruedLiabilitiesForPurchasesCurrent	13081000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4326000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4371000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4127000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4011000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4059000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9114000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	30008000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6297000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23711000
CY2019Q4	adap	Accrued Liabilities For Purchases Current AccruedLiabilitiesForPurchasesCurrent	8782000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11825000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6863000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2126000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2662000
CY2019Q4	us-gaap	Recorded Unconditional Purchase Obligation RecordedUnconditionalPurchaseObligation	5000000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	47000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	56000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27079000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23363000
CY2019	adap	Period Of Agreement Purchase Obligation PeriodOfAgreementPurchaseObligation	P5Y
CY2019	adap	Operating Losses Accrued On Firm Purchase Commitments OperatingLossesAccruedOnFirmPurchaseCommitments	5000000
CY2019	adap	Purchase Commitments Recognized During Period PurchaseCommitmentsRecognizedDuringPeriod	5000000
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	5000000
CY2020	adap	Purchase Commitments Paid Or Invoiced During Period PurchaseCommitmentsPaidOrInvoicedDuringPeriod	5000000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3037000
CY2020Q4	adap	Stockholders Equity Note Show Of Hands Votes Per Share StockholdersEquityNoteShowOfHandsVotesPerShare	1
CY2020Q4	adap	Stockholders Equity Note Show Of Hands Votes Per Share StockholdersEquityNoteShowOfHandsVotesPerShare	1
CY2019Q4	adap	Stockholders Equity Note Show Of Hands Votes Per Share StockholdersEquityNoteShowOfHandsVotesPerShare	1
CY2020Q4	adap	Stockholders Equity Note Show Of Hands Votes Per Share StockholdersEquityNoteShowOfHandsVotesPerShare	1
CY2019Q4	adap	Stockholders Equity Note Show Of Hands Votes Per Share StockholdersEquityNoteShowOfHandsVotesPerShare	1
CY2020Q4	adap	Stockholders Equity Note Show Of Hands Votes Per Share StockholdersEquityNoteShowOfHandsVotesPerShare	1
CY2019Q4	adap	Stockholders Equity Note Show Of Hands Votes Per Share StockholdersEquityNoteShowOfHandsVotesPerShare	1
CY2019Q4	adap	Stockholders Equity Note Poll Votes Per Share StockholdersEquityNotePollVotesPerShare	1
CY2017Q2	adap	Stockholders Equity Note Authority Of Directors To Allot New Shares Or Grant Rights Maximum Aggregate Nominal Amount StockholdersEquityNoteAuthorityOfDirectorsToAllotNewSharesOrGrantRightsMaximumAggregateNominalAmount	257595.00
CY2017Q2	adap	Period Of Authority To Directors To Allot Grant Rights And Covert Any Security PeriodOfAuthorityToDirectorsToAllotGrantRightsAndCovertAnySecurity	P1Y
CY2017Q2	adap	Stockholders Equity Note Authority Of Directors To Allot Shares Or Grant Rights Without First Offering To Existing Shareholders Maximum Aggregate Nominal Amount StockholdersEquityNoteAuthorityOfDirectorsToAllotSharesOrGrantRightsWithoutFirstOfferingToExistingShareholdersMaximumAggregateNominalAmount	257595.00
CY2015Q1	adap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants Maximum Value Per Participant ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumValuePerParticipant	30000
CY2020	adap	Schedule Of Share Based Compensation Granted To Non Executive Directors ScheduleOfShareBasedCompensationGrantedToNonExecutiveDirectors	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on May 11, 2015:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Immediately on grant date</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to a non-executive director on June 23, 2016:</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">25% on the <span style="-sec-ix-hidden:Hidden_s26PqIRLrUqM_s0Zh0T-LA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date and 75% in monthly installments over the following two years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on August 11, 2016:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">100% on the <span style="-sec-ix-hidden:Hidden_LbFjhFfPOkeJjTCbZ-74Gw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date </p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on November 28, 2016:</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;"></span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">25% on the <span style="-sec-ix-hidden:Hidden_M74hjvbsw0yn2iR6qvzdkw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date and 75% in monthly installments over the following two years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on July 3, 2017</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">100% on the <span style="-sec-ix-hidden:Hidden_XRey85dfy0GPEkfddRxumA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Options granted to non-executive directors on June 22, 2018:</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">100% on the <span style="-sec-ix-hidden:Hidden_DgD5oL3OmEOAdT3rpl0KkQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to a non-executive director on July 5, 2018:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">25% on the <span style="-sec-ix-hidden:Hidden_geg-f3A7Bk-CcY_xf3o5jw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date and 75% in monthly instalments over the following two years</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on July 2, 2019:</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">100% on the <span style="-sec-ix-hidden:Hidden_gkGhbDud2kCELUy2HOmxFw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on July 1, 2020:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">100% on the <span style="-sec-ix-hidden:Hidden_5DZCpKJtaUSSGebDKanwMQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date</p></td></tr></table>
CY2015Q1	adap	Share Based Compensation Arrangement By Share Based Payment Award Options Scheme Limit Grants Percentage Of Initial Fully Diluted Share Capital Immediately Following Initial Public Offering ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemeLimitGrantsPercentageOfInitialFullyDilutedShareCapitalImmediatelyFollowingInitialPublicOffering	0.08
CY2015Q1	adap	Share Based Compensation Arrangement By Share Based Payment Award Options Scheme Limit Grants Automatic Annual Increase Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemeLimitGrantsAutomaticAnnualIncreasePercentage	0.04
CY2015Q1	adap	Share Based Compensation Arrangement By Share Based Payment Award Options Schemes Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemesNumber	3
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10414000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11053000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16202000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	11876000
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11401390
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3549298
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5334936
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8195000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1977000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6727000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5663000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	366000
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	1265000
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	1488000
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	1325000
CY2020Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	91643184
CY2020	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2020Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.55
CY2020Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	53554476
CY2020Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.65
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-129930000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-136923000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-95017000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	162000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	242000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	400000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	97000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	162000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	242000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	497000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	162000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	242000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	497000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	796000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1251000
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2009000
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2364000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	156000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	79000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2961000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3694000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9292000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9941000
CY2020Q4	adap	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	1745000
CY2019Q4	adap	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	1413000
CY2020Q4	adap	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	2343000
CY2019Q4	adap	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	2550000
CY2020Q4	adap	Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards	71742000
CY2019Q4	adap	Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards	48837000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	237000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	125000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	85359000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	62866000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	82398000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59172000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2961000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3694000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20329000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16961000
CY2020	adap	Valuation Allowance Deferred Tax Asset Foreign Currency Translation Adjustments ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslationAdjustments	2897000
CY2019	adap	Valuation Allowance Deferred Tax Asset Foreign Currency Translation Adjustments ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslationAdjustments	1435000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	82398000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59172000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20329000
CY2020	adap	Operating Loss Carryforwards And Tax Credit Carryforward Annual Allowance OperatingLossCarryforwardsAndTaxCreditCarryforwardAnnualAllowance	5000000
CY2020Q4	adap	Operating Loss Carryforwards And Tax Credit Carryforward Percentage On Taxable Profit OperatingLossCarryforwardsAndTaxCreditCarryforwardPercentageOnTaxableProfit	0.50
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	46658000
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	51857000
CY2019Q4	adap	Clinical Materials Noncurrent ClinicalMaterialsNoncurrent	2503000

Files In Submission

Name	View Source	Status
0001558370-21-001827-index-headers.html	Edgar Link	pending
0001558370-21-001827-index.html	Edgar Link	pending
0001558370-21-001827.txt	Edgar Link	pending
0001558370-21-001827-xbrl.zip	Edgar Link	pending
adap-20201231.xsd	Edgar Link	pending
adap-20201231x10k.htm	Edgar Link	pending
adap-20201231x10k001.jpg	Edgar Link	pending
adap-20201231x10k002.jpg	Edgar Link	pending
adap-20201231x10k003.jpg	Edgar Link	pending
adap-20201231x10k004.jpg	Edgar Link	pending
adap-20201231x10k005.jpg	Edgar Link	pending
adap-20201231x10k006.jpg	Edgar Link	pending
adap-20201231x10k007.jpg	Edgar Link	pending
adap-20201231x10k008.jpg	Edgar Link	pending
adap-20201231x10k_htm.xml	Edgar Link	completed
adap-20201231xex21d1.htm	Edgar Link	pending
adap-20201231xex23d1.htm	Edgar Link	pending
adap-20201231xex31d1.htm	Edgar Link	pending
adap-20201231xex31d2.htm	Edgar Link	pending
adap-20201231xex32d1.htm	Edgar Link	pending
adap-20201231xex32d2.htm	Edgar Link	pending
adap-20201231xex4d4.htm	Edgar Link	pending
adap-20201231_cal.xml	Edgar Link	unprocessable
adap-20201231_def.xml	Edgar Link	unprocessable
adap-20201231_lab.xml	Edgar Link	unprocessable
adap-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADAP
Adaptimmune Therapeutics PLC Stock $adap

2019 Q4 Form 10-K Financial Statement

#000155837021001827 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADAP Adaptimmune Therapeutics PLC Stock $adap

2019 Q4 Form 10-K Financial Statement

#000155837021001827 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADAP
Adaptimmune Therapeutics PLC Stock $adap